Nonpegylated liposomal doxorubicin (nPLD) in neoadjuvant treatment of local advanced breast cancer (LABC) patients (pts)

被引：0
|
作者：
Rossi, Luigi
Tomao, Federica
Papa, Anselmo
Zoratto, Federica
Ricci, Fabio
Spinelli, Gian Paolo
Lo Russo, Giuseppe
Basso, Enrico
Caprio, Giuliana
Barberi, Simona
Verrico, Monica
Giordani, Erika
Zaccarelli, Eleonora
Rinaldi, Giulia
Stati, Valeria
Pasciuti, Giulia
Strudel, Martina
Tomao, Silverio
机构：
[1] Univ Rome, Santa Maria Goretti Hosp, Dept Medicosurg Sci & Biotechnol, Oncol Unit, Latina, Italy
[2] Dept Gynecol & Obstet, Rome, Italy
[3] Osped SM Goretti, Latina, Italy
[4] Univ Rome, Dept Expt Med & Pathol, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11514
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Safety and activity of nonpegylated liposomal doxorubicin (nPLD) combined with oral metronomic cyclophosphamide (mC) as preoperative treatment for locally advanced breast cancer (BC) patients (pts)
    Andreis, Daniele
    Generali, Daniele Giulio
    Foroni, Chiara
    Bazzola, Letizia
    Cappelletti, Mariarosa
    Zanoni, Vanessa
    Milani, Manuela
    Strina, Carla
    Allevi, Giovanni
    Aguggini, Sergio
    Boni, Ermenegilda
    Giardini, Roberto
    Bertoni, Ramona
    Bottini, Alberto
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] The role of anthracyclines in the treatment of advanced breast cancer - the place of nonpegylated liposomal doxorubicin
    Glogowska, Iwona
    Dubianski, Roman
    Skrzypczyk, Anna
    Pienkowski, Tadeusz
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2010, 6 : A8 - A17
  • [3] Low cardiotoxicity of nonpegylated liposomal doxorubicin (NPLD) in patients (pts) with metastatic breast cancer (MBC) previously exposed to 360 mg/m2 of doxorubicin (D).
    Munoz, E.
    Perez-Garcia, J. M.
    Saura, C.
    Vidal, M.
    Sanchez-Olle, G.
    Bellet, M.
    Gomez, P.
    Di Cosimo, S.
    Baselga, J.
    Cortes, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Clinical risk factors as predictors of potential cardiotoxicity related to nonpegylated liposomal doxorubicin (NPLD) in metastatic breast cancer (MBC) patients (pts) previously treated with conventional anthracyclines (A).
    Munoz-Couselo, E.
    Perez-Garcia, J. M.
    Saura, C.
    Vidal, M.
    Bellet Ezquerra, M.
    Balmana, J.
    Grana, B.
    Gomez Pardo, P.
    De Mattos-Arruda, L.
    Di Cosimo, S.
    Munoz, S.
    Vidal, O.
    Garcia Castro, B.
    Espallargas, R.
    Esteban, V.
    Tabernero, J.
    Baselga, J.
    Cortes, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] A multicenter randomized phase II study of nonpegylated liposomal doxorubicin plus vinorelbine versus nonpegylated liposomal doxorubicin plus cyclophosphamide as first line in locally advanced breast cancer (LABC) or metastatic breast cancer (MBC): Safety results
    Lorusso, V.
    Leo, S.
    Ciccarese, M.
    Giotta, F.
    Bordonaro, R.
    Filippelli, G.
    Del Prete, S.
    Piano, A.
    Gebbia, V.
    Pisconti, S.
    Colucci, G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Biweekly nonpegylated liposomal doxorubicin (M) and docetaxel (T) as neoadjuvant treatment in patients with stage II-III breast cancer
    Alvarez, I.
    Modolell, A.
    Mayordomo, J. I.
    Janariz, J.
    Centelles, M.
    Garcia, J. M.
    Puerto, P.
    Diego, C.
    Madronal, C.
    Burillo-R Andres, M. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer
    Stavridi, Flora
    Palmieri, Carlo
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (12) : 1859 - 1869
  • [8] Multicenter study of nonpegylated liposomal doxorubicin and docetaxel as neoadjuvant treatment in patients with stage II-III breast
    Modolell, A
    Mayordomo, J
    Garcia, JM
    Machengs, I
    Alvarez, I
    Palombo, H
    Yubero, A
    Murillo, L
    Belon, J
    Andres, R
    Burillo, M
    Lambea, J
    Centelles, M
    Tres, A
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S226 - S226
  • [9] Substituting doxorubicin with nonpegylated liposomal doxorubicin (NPLD) in adjuvant/primary chemotherapy for early breast cancer, impact in cardiac function: A pilot study.
    Davidson, N.
    Chalkidou, A.
    Houghton, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Substituting Doxorubicin with Nonpegylated Liposomal Doxorubicin for the Treatment of Early Breast Cancer: Results of a Retrospective Study
    Davidson, Neville
    Camburn, Teresa
    Keary, Ian
    Houghton, David
    [J]. INTERNATIONAL JOURNAL OF BREAST CANCER, 2014, 2014
12345